Abstract
TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Current Molecular Medicine
Title: Differential TNF-Signaling in Chronic Inflammatory Disorders
Volume: 4 Issue: 4
Author(s): Martin H. Holtmann and Markus F. Neurath
Affiliation:
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Abstract: TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Export Options
About this article
Cite this article as:
Holtmann H. Martin and Neurath F. Markus, Differential TNF-Signaling in Chronic Inflammatory Disorders, Current Molecular Medicine 2004; 4 (4) . https://dx.doi.org/10.2174/1566524043360636
DOI https://dx.doi.org/10.2174/1566524043360636 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
Current Pharmaceutical Design Physical Means of Stratum Corneum Barrier Manipulation to Enhance Transdermal Drug Delivery
Current Drug Delivery Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Novel Strategies and Tools for Enhanced Sensitivity in Routine Biomolecule Analytics
Current Pharmaceutical Analysis Autoinflammation and Immunomodulation in Inflammatory Fibromyalgia Syndrome- A Review
Current Rheumatology Reviews Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders
Current Molecular Medicine Mechanisms and Therapeutic Implications of Asthma Circadian Rhythm
Current Respiratory Medicine Reviews Humoral Immunity in Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and Mitochondrial Dysfunction in Sepsis: A Potential Therapy with Mitochondria-Targeted Antioxidants
Infectious Disorders - Drug Targets Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Modulation by Licofelone and Celecoxib of Experimentally Induced Cancer and Preneoplastic Lesions in Mice Exposed to Cigarette Smoke
Current Cancer Drug Targets Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Fibrosis in the Anterior Segments of the Eye
Endocrine, Metabolic & Immune Disorders - Drug Targets A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Pharmacology of Cyclic Peptides: Vancomycin and Oxytocin as Paradigms
Protein & Peptide Letters Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design